413 related articles for article (PubMed ID: 30643192)
21. A seven-gene CpG-island methylation panel predicts breast cancer progression.
Li Y; Melnikov AA; Levenson V; Guerra E; Simeone P; Alberti S; Deng Y
BMC Cancer; 2015 May; 15():417. PubMed ID: 25986046
[TBL] [Abstract][Full Text] [Related]
22. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
23. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.
Vietsch EE; Graham GT; McCutcheon JN; Javaid A; Giaccone G; Marshall JL; Wellstein A
Cancer Genet; 2017 Dec; 218-219():39-50. PubMed ID: 29153095
[TBL] [Abstract][Full Text] [Related]
24. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
25. Methylation status and long-fragment cell-free DNA are prognostic biomarkers for gastric cancer.
Ko K; Kananazawa Y; Yamada T; Kakinuma D; Matsuno K; Ando F; Kuriyama S; Matsuda A; Yoshida H
Cancer Med; 2021 Mar; 10(6):2003-2012. PubMed ID: 33641249
[TBL] [Abstract][Full Text] [Related]
26. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of protein expression and DNA methylation profiles detected by pyrosequencing in invasive breast cancer.
Zmetakova I; Danihel L; Smolkova B; Mego M; Kajabova V; Krivulcik T; Rusnak I; Rychly B; Danis D; Repiska V; Blasko P; Karaba M; Benca J; Pechan J; Fridrichova I
Neoplasma; 2013; 60(6):635-46. PubMed ID: 23906298
[TBL] [Abstract][Full Text] [Related]
28. Circulating Plasma Tumor DNA.
Parsons HA; Beaver JA; Park BH
Adv Exp Med Biol; 2016; 882():259-76. PubMed ID: 26987539
[TBL] [Abstract][Full Text] [Related]
29. SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.
Balgkouranidou I; Chimonidou M; Milaki G; Tsaroucha E; Kakolyris S; Georgoulias V; Lianidou E
Clin Chem Lab Med; 2016 Aug; 54(8):1385-93. PubMed ID: 26741346
[TBL] [Abstract][Full Text] [Related]
30. E74-like Factor 5 Promoter Methylation in Circulating Tumor DNA as a Potential Prognostic Marker in Breast Cancer Patients.
Salimi M; Rastegarpouyani S
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4035-4041. PubMed ID: 38156835
[TBL] [Abstract][Full Text] [Related]
31. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
[TBL] [Abstract][Full Text] [Related]
32. Detection of circulating tumor cells in breast cancer patients: prognostic predictive role.
Turker I; Uyeturk U; Sonmez OU; Oksuzoglu B; Helvaci K; Arslan UY; Budakoglu B; Alkis N; Aksoy S; Zengin N
Asian Pac J Cancer Prev; 2013; 14(3):1601-7. PubMed ID: 23679243
[TBL] [Abstract][Full Text] [Related]
33. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer.
Kioulafa M; Balkouranidou I; Sotiropoulou G; Kaklamanis L; Mavroudis D; Georgoulias V; Lianidou ES
Int J Cancer; 2009 Dec; 125(12):2887-92. PubMed ID: 19551853
[TBL] [Abstract][Full Text] [Related]
34. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients.
Chimonidou M; Tzitzira A; Strati A; Sotiropoulou G; Sfikas C; Malamos N; Georgoulias V; Lianidou E
Clin Biochem; 2013 Feb; 46(3):235-40. PubMed ID: 23006792
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.
Parisi C; Mastoraki S; Markou A; Strati A; Chimonidou M; Georgoulias V; Lianidou ES
Clin Chim Acta; 2016 Oct; 461():156-64. PubMed ID: 27510924
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of
Vagionas A; Balgkouranidou I; Koukaki T; Biziota E; Amarantidis K; Kakolyris S; Xenidis N
Hippokratia; 2023; 27(1):7-11. PubMed ID: 38533226
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of KiSS1 as a Prognostic Biomarker in North Indian Breast Cancer Cases.
Singh R; Bhatt ML; Singh SP; Kumar V; Goel MM; Mishra DP; Kumar R
Asian Pac J Cancer Prev; 2016; 17(4):1789-95. PubMed ID: 27221854
[TBL] [Abstract][Full Text] [Related]
38. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
39. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
[TBL] [Abstract][Full Text] [Related]
40. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma.
Kristensen LS; Hansen JW; Kristensen SS; Tholstrup D; Harsløf LB; Pedersen OB; De Nully Brown P; Grønbæk K
Clin Epigenetics; 2016; 8(1):95. PubMed ID: 27610206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
